Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Given Average Recommendation of “Hold” by Brokerages

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) has received an average rating of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $48.00.

A number of equities analysts have recently issued reports on SNSE shares. BTIG Research started coverage on shares of Sensei Biotherapeutics in a report on Thursday, June 11th. They issued a “buy” rating and a $55.00 price target for the company. Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Leerink Partners assumed coverage on shares of Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective on the stock. Wall Street Zen cut shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Loop Capital set a $50.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, May 28th.

Insider Transactions at Sensei Biotherapeutics

In related news, major shareholder Millennium Management Llc sold 8,151 shares of the stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $31.01, for a total value of $252,762.51. Following the sale, the insider directly owned 133,986 shares of the company’s stock, valued at approximately $4,154,905.86. This represents a 5.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder James Peyer sold 25,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the sale, the insider directly owned 130,142 shares in the company, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders purchased 46,980 shares of company stock worth $1,341,669 and sold 48,067 shares worth $1,204,939. 7.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several hedge funds have recently modified their holdings of SNSE. Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after purchasing an additional 1,100 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics during the 1st quarter worth about $4,188,000. Finally, Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics during the 1st quarter worth about $22,758,000. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Stock Up 6.5%

Shares of SNSE opened at $13.85 on Tuesday. The company has a 50-day simple moving average of $22.94 and a 200-day simple moving average of $18.96. The company has a market capitalization of $18.56 million, a PE ratio of -0.10 and a beta of -0.25. Sensei Biotherapeutics has a 52-week low of $5.86 and a 52-week high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83).

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.